- Home
- EVAX vs RDHL Comparison
EVAX vs RDHL Comparison
Compare EVAX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- RDHL
- Stock Information
- Founded
- EVAX 2008
- RDHL 2009
- Country
- EVAX Denmark
- RDHL Israel
- Employees
- EVAX N/A
- RDHL N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- RDHL Health Care
- Exchange
- EVAX Nasdaq
- RDHL Nasdaq
- Market Cap
- EVAX 15.1M
- RDHL 4.3M
- IPO Year
- EVAX 2021
- RDHL N/A
- Fundamental
- Price
- EVAX $2.64
- RDHL $2.15
- Analyst Decision
- EVAX Strong Buy
- RDHL
- Analyst Count
- EVAX 2
- RDHL 0
- Target Price
- EVAX $10.00
- RDHL N/A
- AVG Volume (30 Days)
- EVAX 101.0K
- RDHL 18.4K
- Earning Date
- EVAX 08-13-2025
- RDHL 08-28-2025
- Dividend Yield
- EVAX N/A
- RDHL N/A
- EPS Growth
- EVAX N/A
- RDHL N/A
- EPS
- EVAX N/A
- RDHL N/A
- Revenue
- EVAX $3,293,000.00
- RDHL $8,042,999.00
- Revenue This Year
- EVAX N/A
- RDHL $381.91
- Revenue Next Year
- EVAX N/A
- RDHL N/A
- P/E Ratio
- EVAX N/A
- RDHL N/A
- Revenue Growth
- EVAX 2555.64
- RDHL 23.17
- 52 Week Low
- EVAX $1.20
- RDHL $1.71
- 52 Week High
- EVAX $17.75
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- EVAX 55.56
- RDHL 64.10
- Support Level
- EVAX $2.26
- RDHL $2.00
- Resistance Level
- EVAX $2.60
- RDHL $2.08
- Average True Range (ATR)
- EVAX 0.21
- RDHL 0.09
- MACD
- EVAX -0.02
- RDHL 0.03
- Stochastic Oscillator
- EVAX 51.32
- RDHL 100.00
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.